PD41-09 MOVING BEYOND PSA: IDENTIFYING THE OPTIMAL DIAGNOSTIC STRATEGY TO ASSESS PROSTATE CANCER RISK (2022)

You have accessJournal of UrologyCME1 May 2022PD41-09 MOVING BEYOND PSA: IDENTIFYING THE OPTIMAL DIAGNOSTIC STRATEGY TO ASSESS PROSTATE CANCER RISK Douglas Cheung, Diana Magee, Thomas Stonier, Andrew Briggs, Bart Ferket, Antonio Finelli, Girish Kulkarni, Andrew Vickers, Sigrid Carlsson, and James Eastham Douglas CheungDouglas Cheung More articles by this author , Diana MageeDiana Magee More articles by this author , Thomas StonierThomas Stonier More articles by this author , Andrew BriggsAndrew Briggs More articles by this author , Bart FerketBart Ferket More articles by this author , Antonio FinelliAntonio Finelli More articles by this author , Girish KulkarniGirish Kulkarni More articles by this author , Andrew VickersAndrew Vickers More articles by this author , Sigrid CarlssonSigrid Carlsson More articles by this author , and James EasthamJames Eastham More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002602.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Diagnostic strategies based on biomarkers and/or magnetic resonance imaging (MRI) may better select men whose PSA test is unlikely to be clinically significant prostate cancer (PCa) from men who may harbor life threatening disease. However, there is limited evidence regarding the combined use of biomarkers with MRI, and which sequence is most efficient. We compared the clinical- and cost-effectiveness of multiple strategies for the diagnosis of PCa. METHODS: A clinical decision tree was constructed (TreeAgePro 2021) to evaluate biomarker and MRI strategies versus systematic biopsy. In addition to solo testing, combination pathways of biomarkers and MRI with sequential testing in positive-reflexive (e.g. to locate the lesion) and negative-reflexive (e.g. to confirm the negative) manners were evaluated. Patients with a positive MRI and/or biomarker were biopsied. The base case was a biopsy-naïve man with a worrisome PSA for initial diagnosis. Our co-primary outcomes were: I) clinically significant (Gleason 3+4 or higher) and II) non-clinically significant PCa, III) biopsies avoided, and IV) mean cost (U.S. [$] and U.K. [£]) per patient. Model parameters were populated from a literature search of electronic databases (i.e. MEDLINE, PubMed). Inputs for diagnostic performance were preferentially identified using template biopsy reference standards. Cost data were selected from primary sources (e.g. governmental agencies) where available. RESULTS: Most combination strategies and MRI-alone were superior to a recommendation that all men with a worrisome PSA test undergo systematic biopsy (Table 1). Additional testing increased detection of clinically significant PCa (1%-19%), reduced overdiagnosing non-clinically significant PCa (2%-18%), while sparing many men from biopsy (5%-26%). There was a modest additional cost from $96-$933/£214-£1,161. Approaches that optimized clinical consequences and cost were biomarker with positive reflexive MRI or MRI followed by negative reflex biomarker. Our results were robust to sensitivity analyses exploring PCa prevalence and target-only biopsy. CONCLUSIONS: Cost-effective pre-biopsy strategies including a combination of MRI and biomarker better identify men at higher risk for clinically significant PCa while avoiding biopsy in lower risk individuals. Source of Funding: D.C.C.'s work was supported in part by the Canadian Institutes of Health Research Canada Graduate Doctoral Scholarship, Hold'em for Life Oncology Clinician Scientist/Fellowship, Canadian Association for Healthcare Reimbursement Research Scholarship, and Clinician Investigator Program-Ministry of Health Scholarship funding. A.B.’s, A.V.’s, S.V.C.’s and J.A.E.’s work was supported in part by funding from National Institutes of Health/National Cancer Institute (P30-CA008748) and Sidney Kimmel Center for Prostate and Urologic Cancers. S.V.C. was further supported by the National Institutes of Health/National Cancer Institute (K22-CA234400 and U01-CA199338-02) and the Prevent Cancer Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e692 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Douglas Cheung More articles by this author Diana Magee More articles by this author Thomas Stonier More articles by this author Andrew Briggs More articles by this author Bart Ferket More articles by this author Antonio Finelli More articles by this author Girish Kulkarni More articles by this author Andrew Vickers More articles by this author Sigrid Carlsson More articles by this author James Eastham More articles by this author Expand All Advertisement PDF DownloadLoading ...